Cell therapies present an entirely new paradigm in drug development. Within this class,
immune cell therapies are among the most advanced, having already demonstrated …

Different immunotherapeutic approaches have proved to be of significant clinical value to
many patients with different types of advanced cancer. However, we need more precise …

Chimeric antigen receptor (CAR) T cell therapy is revolutionizing cancer immunotherapy for
patients with B cell malignancies and is now being developed for solid tumors and chronic …

The redirection of T cells against tumors holds much promise for the treatment of cancer.
Two main approaches for T-cell redirection involve their genetic modification with chimeric …

Bispecific antibodies (bsAbs) refer to a large family of molecules that recognize two different
epitopes or antigens. Although a series of challenges, especially immunogenicity and chain …

Bispecific T cell engagers (BiTEs) are bispecific antibodies that redirect T cells to target
antigen-expressing tumors. We hypothesized that BiTE-secreting T cells could be a valuable …

No single cancer immunotherapy will likely defeat all evasion mechanisms of solid tumors,
including plasticity of tumor antigen expression and active immune suppression by the tumor …

Chimeric antigen receptor (CAR) T-cell therapy targeting T-cell acute lymphoblastic
leukemia (T-ALL) faces limitations such as antigen selection and limited T-cell persistence …

There is a need to improve outcomes for patients with recurrent and/or refractory
hematological malignancies. Immunotherapy holds the promise to meet this need, because …

Multiple myeloma is the second most common hematological malignancy in adults and
remains an incurable disease. B cell maturation antigen (BCMA)–directed immunotherapy …